Research Article
Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience
Table 1
Patients’ characteristics and Chi square test results.
| | Characteristics | No. of patients (%) | No. of no Ki-67 reduction or increase (%) | No. of Ki-67 1–20% reduction (%) | No. of Ki-67 >20% reduction (%) | |
| | — | 82 (100) | 23 (28.1) | 23 (28.1) | 36 (43.8) | — | | Age (years) | | <50 | 36 (43.9) | 9 (39.1) | 11(47.8) | 16 (44.4) | 0.8350 | | >50 | 46(56.1) | 14 (60.9) | 12 (52.2) | 20 (55.6) |
| | BMI | | <25 | 40 (48.8) | 8 (34.7) | 15 (65.2) | 17 (47.2) | 0.3285 | | 25–30 | 30 (36.6) | 10 (43.5) | 6 (26.1) | 14 (38.9) | | >30 | 12 (14.6) | 5 (21.8) | 2 (8.7) | 5 (13.9) |
| | Histotype | | Ductal | 67 (81.7) | 18 (78.3) | 18 (78.3) | 31 (86.1) | 0.6526 | | Lobular | 9 (11.0) | 3 (13.0) | 4 (17.4) | 2 (5.6) | | Mixed | 6 (7.3) | 2 (8.7) | 1 (4.3) | 3 (8.3) |
| | Grade | | 2 | 23 (28.0) | 4 (17.4) | 10 (43.5) | 9 (25.0) | 0.1241 | | 3 | 59 (72.0) | 19 (82.6) | 13 (56.5) | 27 (75.0) |
| | Lymphovascular invasion | | Absent | 46 (56.4) | 10 (43.5) | 16 (69.6) | 20 (55.6) | 0.2542 | | Present | 36 (43.6) | 13(56.5) | 7 (30.4) | 16 (44.4) |
| | Breast cancer phenotype | | Luminal B HER-2 (−) | 35 (42.7) | 5 (21.8) | 8 (34.8) | 22 (61.2) | 0.0035 | | Luminal B HER-2 (+) | 16 (19.5) | 3 (13.0) | 9 (39.1) | 4 (11.1) | | HER-2 (+) | 10 (12.2) | 6 (26.1) | 1 (4.3) | 3 (8.3) | | Triple negative | 21 (25.6) | 9 (39.1) | 5 (21.8) | 7 (19.4) |
| | Clinical stage | | 1 | 23 (28.1) | 7 (30.5) | 6 (26.1) | 10 (27.8) | 0.7102 | | 2 | 39 (47.5) | 11 (47.8) | 12 (52.1) | 16 (44.4) | | 3 | 17 (20.8) | 3 (13.0) | 5 (21.8) | 9 (25.0) | | 4 | 3 (3.6) | 2 (8.7) | 0 (0.0) | 1 (2.8) |
|
|
BMI, body mass index; HER-2, Human Epidermal Growth Factor Receptor 2.
|
